These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 36346550)

  • 1. CARs: a new approach for the treatment of autoimmune diseases.
    Sun Y; Yuan Y; Zhang B; Zhang X
    Sci China Life Sci; 2023 Apr; 66(4):711-728. PubMed ID: 36346550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric Antigen Receptor Based Therapy as a Potential Approach in Autoimmune Diseases: How Close Are We to the Treatment?
    Sadeqi Nezhad M; Seifalian A; Bagheri N; Yaghoubi S; Karimi MH; Adbollahpour-Alitappeh M
    Front Immunol; 2020; 11():603237. PubMed ID: 33324420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harnessing the inherent power of chimeric antigen receptor (CAR)-expressing regulatory T cells (CAR-Tregs) to treat autoimmune-related disorders.
    Kahmini FR; Shahgaldi S
    Mol Biol Rep; 2022 May; 49(5):4069-4078. PubMed ID: 35534581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of CAR-T cell technology in autoimmune diseases and human immunodeficiency virus infection treatment.
    Adabi N; Pordel S; Rezaee MA; Shobeiri FS; Shobeiri SS
    J Gene Med; 2023 May; 25(5):e3484. PubMed ID: 36781390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR Treg: A new approach in the treatment of autoimmune diseases.
    Beheshti SA; Shamsasenjan K; Ahmadi M; Abbasi B
    Int Immunopharmacol; 2022 Jan; 102():108409. PubMed ID: 34863655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance.
    Zhang Q; Lu W; Liang CL; Chen Y; Liu H; Qiu F; Dai Z
    Front Immunol; 2018; 9():2359. PubMed ID: 30369931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR T cells for treating autoimmune diseases.
    Blache U; Tretbar S; Koehl U; Mougiakakos D; Fricke S
    RMD Open; 2023 Nov; 9(4):. PubMed ID: 37996128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoimmunity as a target for chimeric immune receptor therapy: A new vision to therapeutic potential.
    Haddadi MH; Hajizadeh-Saffar E; Khosravi-Maharlooei M; Basiri M; Negahdari B; Baharvand H
    Blood Rev; 2020 May; 41():100645. PubMed ID: 31813654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology.
    Koristka S; Kegler A; Bergmann R; Arndt C; Feldmann A; Albert S; Cartellieri M; Ehninger A; Ehninger G; Middeke JM; Bornhäuser M; Schmitz M; Pietzsch J; Akgün K; Ziemssen T; Steinbach J; Bachmann MP
    J Autoimmun; 2018 Jun; 90():116-131. PubMed ID: 29503042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frontiers in CAR-T cell therapy for autoimmune diseases.
    Li YR; Lyu Z; Chen Y; Fang Y; Yang L
    Trends Pharmacol Sci; 2024 Sep; 45(9):839-857. PubMed ID: 39147651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations.
    Terry LV; Oo YH
    Front Immunol; 2020; 11():565518. PubMed ID: 33072105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes.
    Tenspolde M; Zimmermann K; Weber LC; Hapke M; Lieber M; Dywicki J; Frenzel A; Hust M; Galla M; Buitrago-Molina LE; Manns MP; Jaeckel E; Hardtke-Wolenski M
    J Autoimmun; 2019 Sep; 103():102289. PubMed ID: 31176558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory CAR-T cells in autoimmune diseases: Progress and current challenges.
    Riet T; Chmielewski M
    Front Immunol; 2022; 13():934343. PubMed ID: 36032080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory T cell therapy: Current and future design perspectives.
    Rana J; Biswas M
    Cell Immunol; 2020 Oct; 356():104193. PubMed ID: 32823038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulating the regulators: Is introduction of an antigen-specific approach in regulatory T cells the next step to treat autoimmunity?
    Janssens I; Cools N
    Cell Immunol; 2020 Dec; 358():104236. PubMed ID: 33137651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor T-cell therapy beyond cancer: current practice and future prospects.
    Zhang PF; Xie D; Li Q
    Immunotherapy; 2020 Sep; 12(13):1021-1034. PubMed ID: 32727249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases.
    Su M; Zhao C; Luo S
    Autoimmun Rev; 2022 Jan; 21(1):102931. PubMed ID: 34481941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases.
    Chen Y; Sun J; Liu H; Yin G; Xie Q
    J Immunol Res; 2019; 2019():5727516. PubMed ID: 32083141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advancements and challenges in CAR T cell therapy in autoimmune diseases.
    Schett G; Müller F; Taubmann J; Mackensen A; Wang W; Furie RA; Gold R; Haghikia A; Merkel PA; Caricchio R; D'Agostino MA; Locatelli F; June CH; Mougiakakos D
    Nat Rev Rheumatol; 2024 Sep; 20(9):531-544. PubMed ID: 39107407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are chimeric antigen receptor T cells (CAR-T cells) the future in immunotherapy for autoimmune diseases?
    Santamaria-Alza Y; Vasquez G
    Inflamm Res; 2021 Jun; 70(6):651-663. PubMed ID: 34018005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.